Skip to main content
. 2022 Oct 28;7(8):1488–1495. doi: 10.1182/bloodadvances.2022008344

Table 5.

All-grade AEs reported in >5% of patients (N = 42)

All-grade AE n (%)
Hematologic toxicity
 Neutropenia 22 (52.4)
 Febrile neutropenia 6 (14.3)
 Anemia 6 (14.3)
Nonhematologic toxicity
 Constipation 18 (42.9)
 Fatigue 17 (40.5)
 Infusion-related reaction 16 (38.1)
 Diarrhea 14 (33.3)
 Nausea 13 (31.0)
 Peripheral sensory neuropathy 13 (31.0)
 Cough 12 (28.6)
 Alopecia 10 (23.8)
 Arthralgia 9 (21.4)
 Vomiting 9 (21.4)
 Back pain 8 (19.0)
 Headache 8 (19.0)
 Insomnia 7 (16.7)
 Upper respiratory tract infection 7 (16.7)
 Abdominal pain 6 (14.3)
 Dysgeusia 6 (14.3)
 Sinusitis 6 (14.3)
 Myalgia 5 (11.9)
 Pyrexia 5 (11.9)
 Rhinorrhea 5 (11.9)